121 related articles for article (PubMed ID: 28162293)
1. Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors.
Leon LA; Antón-Aparicio LM
Redox Biol; 2015 Aug; 5():422. PubMed ID: 28162293
[TBL] [Abstract][Full Text] [Related]
2. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.
León-Mateos L; Mosquera J; Antón Aparicio L
Redox Biol; 2015 Dec; 6():421-425. PubMed ID: 26386874
[TBL] [Abstract][Full Text] [Related]
3. [Angiogenesis and renal cell carcinoma].
Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
[TBL] [Abstract][Full Text] [Related]
4. Rho kinase inhibition mitigates sunitinib-induced rise in arterial pressure and renal vascular resistance but not increased renal sodium reabsorption.
Grisk O; Koenen A; Meissner T; Donner A; Braun D; Steinbach A; Glöckl G; Zimmermann U; Evert K; Evert M; Katsari E; Löhn M; Plettenburg O; Rettig R
J Hypertens; 2014 Nov; 32(11):2199-210; discussion 2110. PubMed ID: 25275248
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
Kruzliak P; Novák J; Novák M
Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of hypertension side effects induced by sunitinib.
Aparicio-Gallego G; Afonso-Afonso FJ; León-Mateos L; Fírvida-Pérez JL; Vázquez-Estévez S; Lázaro-Quintela M; Ramos-Vázquez M; Fernández-Calvo O; Campos-Balea B; Antón-Aparicio LM
Anticancer Drugs; 2011 Jan; 22(1):1-8. PubMed ID: 20938340
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.
Eechoute K; van der Veldt AA; Oosting S; Kappers MH; Wessels JA; Gelderblom H; Guchelaar HJ; Reyners AK; van Herpen CM; Haanen JB; Mathijssen RH; Boven E
Clin Pharmacol Ther; 2012 Oct; 92(4):503-10. PubMed ID: 22948895
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
9. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.
Griffioen AW; Mans LA; de Graaf AMA; Nowak-Sliwinska P; de Hoog CLMM; de Jong TAM; Vyth-Dreese FA; van Beijnum JR; Bex A; Jonasch E
Clin Cancer Res; 2012 Jul; 18(14):3961-3971. PubMed ID: 22573349
[TBL] [Abstract][Full Text] [Related]
10. Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
Bilen MA; Zurita AJ; Ilias-Khan NA; Chen HC; Wang X; Kearney AY; Hodges S; Jonasch E; Huang S; Khakoo AY; Tannir NM
Oncologist; 2015 Oct; 20(10):1140-8. PubMed ID: 26306901
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic therapy: concept to clinic.
Young RJ; Reed MW
Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.
Bussolati B; Dunk C; Grohman M; Kontos CD; Mason J; Ahmed A
Am J Pathol; 2001 Sep; 159(3):993-1008. PubMed ID: 11549592
[TBL] [Abstract][Full Text] [Related]
15. Murine colitis treated with multitargeted tyrosine kinase inhibitors.
Knod JL; Crawford K; Dusing M; Frischer JS
J Surg Res; 2016 Feb; 200(2):501-7. PubMed ID: 26521099
[TBL] [Abstract][Full Text] [Related]
16. Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells.
Kim JY; Hwang J; Lee SH; Lee HJ; Jelinek J; Jeong H; Lim JS; Kim JM; Song KS; Kim BH; Lee S; Kim J
Clin Epigenetics; 2015; 7():99. PubMed ID: 26380584
[TBL] [Abstract][Full Text] [Related]
17. From theoretical synergy to clinical supra-additive toxicity.
Soria JC; Massard C; Izzedine H
J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
[No Abstract] [Full Text] [Related]
18. Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events.
Imano H; Kato R; Ijiri Y; Hayashi T
Toxicol In Vitro; 2021 Mar; 71():105063. PubMed ID: 33271325
[TBL] [Abstract][Full Text] [Related]
19. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.
Versmissen J; Mirabito Colafella KM; Koolen SLW; Danser AHJ
Cardiovasc Res; 2019 Apr; 115(5):904-914. PubMed ID: 30726882
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]